Abbott Receives Approval From Anvisa For Ultreon™, Imaging Technology That Uses Artificial Intelligence For Coronary Arteries

Imaging Technology

The National Health Surveillance Agency (Anvisa) recently gave its latest optical coherence tomography (OCT) imaging platform with the new UltreonTM Software its seal of approval, according to Abbott. In order to give clinicians an expanded, comprehensive image of coronary blood flow and blockages to support clinical decision-making and provide the optimal paths for therapy, this cutting-edge imaging technology integrates optical coherence tomography (OCT) with artificial intelligence (AI).

The certification in Brazil comes after the recent FDA clearance, US regulatory agency, and CE Mark approval in Europe, giving interventional cardiologists who want to use the most modern imaging technology more access to the most advanced OCT imaging platform. As a result of the integration of AI. UltreonTM Software with Abbott’s Dragonfly OPTISTM Imaging Catheter and PressureWire XTM Guidewire, doctors now have access to a wide range of tools for evaluating coronary blood flow and obstructions, which enhances patient treatment planning.

With the help of Abbott’s brand-new UltreonTM Software for OCT, doctors may now get an automated, thorough image of the arteries to help with decision-making. Stents can be deployed precisely thanks to UltreonTM Software’s side-by-side perspective. The greatest patient care is only possible with the use of these cutting-edge technologies.

Clinical professionals consider cutting-edge technologies to be essential components of giving the greatest patient care, according to a yearly Abbott survey dubbed Beyond Intervention. According to the survey, 83.2% of doctors concur that developments in diagnostic and therapeutic technologies, including OCT, have led to real gains in patient care.

Emerging technologies like UltreonTM are crucial in deciding the optimal course of patient care as cardiologists continue to adopt OCT and move away from conventional imaging techniques like angiography. In addition, UltreonTM Software’s artificial intelligence enables doctors to implant stents precisely where they are required by autonomously detecting calcium and artery sizes.

“The launch of Ultreon™ Software for OCT in Brazil demonstrates Abbott’s commitment to continued innovation in the global vascular community through the latest medical devices and technologies”, Recent data show that when OCT is combined with Abbott’s MLD MAX algorithm , a standardized workflow helps guide and optimize stent implantation decisions and clinicians change their treatment strategy in 88% of coronary artery blockages .”Abbott’s latest technologies play a vital role in improving patient cardiovascular care and achieving optimal outcomes during and after the intervention,”

Ivo Preuss , General Manager of Abbott’s Vascular Division in Brazil

Next Post

The Future of Medicare and Value-Based Care | NextGen Healthcare

Future of Medicare : In his first podcast for the New Year, NextGen®️ Advisor Graham Brown is joined by Vytalize Health’s CEO and CMO to discuss the growing benefits of participating in an ACO.  
Featured Video Play Icon